Search

Your search keyword '"Martelletti, Paolo"' showing total 2,021 results
Start Over Author "Martelletti, Paolo"
2,021 results on '"Martelletti, Paolo"'

156. Excellent Response to OnabotulinumtoxinA: Different Definitions, Different Predictors

Author

Ornello, Raffaele, primary, Baraldi, Carlo, additional, Ahmed, Fayyaz, additional, Negro, Andrea, additional, Miscio, Anna Maria, additional, Santoro, Antonio, additional, Alpuente, Alicia, additional, Russo, Antonio, additional, Silvestro, Marcello, additional, Cevoli, Sabina, additional, Brunelli, Nicoletta, additional, Vernieri, Fabrizio, additional, Grazzi, Licia, additional, Pani, Luca, additional, Andreou, Anna, additional, Lambru, Giorgio, additional, Frattale, Ilaria, additional, Kamm, Katharina, additional, Ruscheweyh, Ruth, additional, Russo, Marco, additional, Torelli, Paola, additional, Filatova, Elena, additional, Latysheva, Nina, additional, Gryglas-Dworak, Anna, additional, Straburzyński, Marcin, additional, Butera, Calogera, additional, Colombo, Bruno, additional, Filippi, Massimo, additional, Pozo-Rosich, Patricia, additional, Martelletti, Paolo, additional, Guerzoni, Simona, additional, and Sacco, Simona, additional

Published
2022
Full Text
View/download PDF

158. Excellent Response to OnabotulinumtoxinA : Different Definitions, Different Predictors

Author

Ornello, Raffaele, Baraldi, Carlo, Ahmed, Fayyaz, Negro, Andrea, Miscio, Anna Maria, Santoro, Antonio, Alpuente, Alicia, Russo, Antonio, Silvestro, Marcello, Cevoli, Sabina, Brunelli, Nicoletta, Vernieri, Fabrizio, Grazzi, Licia, Pani, Luca, Andreou, Anna P, Lambru, Giorgio, Frattale, Ilaria, Kamm, Katharina, Ruscheweyh, Ruth, Russo, Marco, Torelli, Paola, Filatova, Elena, Latysheva, Nina, Gryglas-Dworak, Anna, Straburzyński, Marcin, Butera, Calogera, Colombo, Bruno, Filippi, Massimo, Pozo-Rosich, Patricia, Martelletti, Paolo, Guerzoni, Simona, Sacco, Simona, Universitat Autònoma de Barcelona, Ornello, Raffaele, Baraldi, Carlo, Ahmed, Fayyaz, Negro, Andrea, Miscio, Anna Maria, Santoro, Antonio, Alpuente, Alicia, Russo, Antonio, Silvestro, Marcello, Cevoli, Sabina, Brunelli, Nicoletta, Vernieri, Fabrizio, Grazzi, Licia, Pani, Luca, Andreou, Anna, Lambru, Giorgio, Frattale, Ilaria, Kamm, Katharina, Ruscheweyh, Ruth, Russo, Marco, Torelli, Paola, Filatova, Elena, Latysheva, Nina, Gryglas-Dworak, Anna, Straburzyński, Marcin, Butera, Calogera, Colombo, Bruno, Filippi, Massimo, Pozo-Rosich, Patricia, Martelletti, Paolo, Guerzoni, Simona, Sacco, Simona, Institut Català de la Salut, [Ornello R] Neuroscience Section, Department of Applied Clinical Sciences and Biotechnology, University of L’Aquila, L’Aquila, Italy. [Baraldi C] Digital and Predictive Medicine, Pharmacology and Clinical Metabolic Toxicology-Headache Center and Drug Abuse-Laboratory of Clinical Pharmacology and Pharmacogenomics, Department of Specialist Medicines, AOU Policlinico di Modena, Modena, Italy. [Ahmed F] Department of Neurosciences, Hull University Teaching Hospitals, Hull, UK. [Negro A] Department of Clinical and Molecular Medicine, Faculty of Medicine and Psychology, Sant’Andrea Hospital, Sapienza University, Rome, Italy. [Miscio AM, Santoro A] Headache Center, Unit of Neurology, Fondazione IRCCS 'Casa Sollievo Della Sofferenza', San Giovanni Rotondo, Italy. [Alpuente A, Pozo-Rosich P] Unitat de Cefalea, Servei de Neurologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Grup de Recerca en Cefalea i Dolor Neurològic, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain, and Vall d'Hebron Barcelona Hospital Campus

Subjects
chronic migraine, onabotulinumtoxinA, predictors of response, excellent responders, Botulinum Toxins, enfermedades del sistema nervioso::enfermedades del sistema nervioso central::enfermedades cerebrales::trastornos con cefaleas::cefaleas primarias::trastornos migrañosos [ENFERMEDADES], Health, Toxicology and Mutagenesis, Migraine Disorders, Excellent responders, acciones y usos químicos::acciones tóxicas::noxas::neurotoxinas [COMPUESTOS QUÍMICOS Y DROGAS], Predictors of response, Otros calificadores::Otros calificadores::/farmacoterapia [Otros calificadores], Migranya - Tractament, Other subheadings::Other subheadings::/drug therapy [Other subheadings], Type A, Neurotoxines - Ús terapèutic, Humans, Chemical Actions and Uses::Toxic Actions::Noxae::Neurotoxins [CHEMICALS AND DRUGS], Other subheadings::/therapeutic use [Other subheadings], Botulinum Toxins, Type A, Nervous System Diseases::Central Nervous System Diseases::Brain Diseases::Headache Disorders::Headache Disorders, Primary::Migraine Disorders [DISEASES], Chronic migraine, Otros calificadores::/uso terapéutico [Otros calificadores], Chronic Disease, Female, Headache, Treatment Outcome, Public Health, Environmental and Occupational Health, Onabotulinumtoxina, Avaluació de resultats (Assistència sanitària)
Abstract

Chronic migraine; OnabotulinumtoxinA; Predictors of response Migraña crónica; OnabotulinumtoxinA; Predictores de respuesta Migranya crònica; OnabotulinumtoxinA; Predictors de resposta The identification of patients who can benefit the most from the available preventive treatments is important in chronic migraine. We explored the rate of excellent responders to onabotulinumtoxinA in a multicenter European study and explored the predictors of such response, according to different definitions. A pooled analysis on chronic migraineurs treated with onabotulinumtoxinA and followed-up for, at least, 9 months was performed. Excellent responders were defined either as patients with a ≥75% decrease in monthly headache days (percent-based excellent responders) or as patients with

Published
2022

161. Correction to: Hormonal contraceptives and risk of ischemic stroke in women with migraine: a consensus statement from the European Headache Federation (EHF) and the European Society of Contraception and Reproductive Health (ESC)

Author

Sacco, Simona, Merki-Feld, Gabriele S., Ægidius, Karen Lehrmann, Bitzer, Johannes, Canonico, Marianne, Kurth, Tobias, Lampl, Christian, Lidegaard, Øjvind, Anne MacGregor, E., MaassenVanDenBrink, Antoinette, Mitsikostas, Dimos-Dimitrios, Nappi, Rossella Elena, Ntaios, George, Sandset, Per Morten, Martelletti, Paolo, and on behalf of the European Headache Federation (EHF) and the European Society of Contraception and Reproductive Health (ESC)

Published
2018
Full Text
View/download PDF

162. Effect of exogenous estrogens and progestogens on the course of migraine during reproductive age: a consensus statement by the European Headache Federation (EHF) and the European Society of Contraception and Reproductive Health (ESCRH)

Author

Sacco, Simona, Merki-Feld, Gabriele S., Ægidius, Karen Lehrmann, Bitzer, Johannes, Canonico, Marianne, Gantenbein, Andreas R., Kurth, Tobias, Lampl, Christian, Lidegaard, Øjvind, Anne MacGregor, E., MaassenVanDenBrink, Antoinette, Mitsikostas, Dimos-Dimitrios, Nappi, Rossella Elena, Ntaios, George, Paemeleire, Koen, Sandset, Per Morten, Terwindt, Gisela Marie, Vetvik, Kjersti Grøtta, Martelletti, Paolo, and on behalf of the European Headache Federation (EHF), the European Society of Contraception and Reproductive Health (ESCRH)

Published
2018
Full Text
View/download PDF

168. A Pilot Study on the Association of Lead, 8-Hydroxyguanine, and Malondialdehyde Levels in Opium Addicts’ Blood Serum with Illicit Drug Use and Non-Addict Persons

Author

Hesaruiyeh, Farzaneh Allahdinian, primary, Rajabi, Saeed, additional, Motamed-Jahromi, Mohadeseh, additional, Sarhadi, Mohammad, additional, Bell, Michelle L., additional, Khaksefidi, Razieh, additional, Sarhadi, Somayeh, additional, Mohammadi, Leili, additional, Dua, Kamal, additional, Mohammadpour, Amin, additional, and Martelletti, Paolo, additional

Published
2022
Full Text
View/download PDF

171. Headache onset after vaccination against SARS-CoV-2:a systematic literature review and meta-analysis

Author

Castaldo, Matteo, Waliszewska-Prosół, Marta, Koutsokera, Maria, Robotti, Micaela, Straburzyński, Marcin, Apostolakopoulou, Loukia, Capizzi, Mariarita, Çibuku, Oneda, Ambat, Fidel Dominique Festin, Frattale, Ilaria, Gadzhieva, Zukhra, Gallo, Erica, Gryglas-Dworak, Anna, Halili, Gleni, Jusupova, Asel, Koperskaya, Yana, Leheste, Alo-Rainer, Manzo, Maria Laura, Marcinnò, Andrea, Marino, Antonio, Mikulenka, Petr, Ong, Bee Eng, Polat, Burcu, Popovic, Zvonimir, Rivera-Mancilla, Eduardo, Roceanu, Adina Maria, Rollo, Eleonora, Romozzi, Marina, Ruscitto, Claudia, Scotto di Clemente, Fabrizio, Strauss, Sebastian, Taranta, Valentina, Terhart, Maria, Tychenko, Iryna, Vigneri, Simone, Misiak, Blazej, Martelletti, Paolo, and Raggi, Alberto

Subjects
Adverse Event, SARS-CoV-2, COVID-19/prevention & control, Vaccination, adverse event, Headache, Vaccination/adverse effects, COVID-19, Headache/etiology, General Medicine, chadox1, bnt162b2, Anesthesiology and Pain Medicine, SDG 3 - Good Health and Well-being, Humans, BNT162b2, ChAdOx1, Neurology (clinical), BNT162 Vaccine, covid-19, headache, sars-cov-2, vaccination, bnt162 vaccine, humans
Abstract

Background Vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are used to reduce the risk of developing Coronavirus Disease 2019 (COVID-19). Despite the significant benefits in terms of reduced risk of hospitalization and death, different adverse events may present after vaccination: among them, headache is one of the most common, but nowadays there is no summary presentation of its incidence and no description of its main features. Methods We searched PubMed and EMBASE covering the period between January 1st 2020 and August 6th, 2021, looking for record in English and with an abstract and using three main search terms (with specific variations): COVID-19/SARS-CoV-2; Vaccination; headache/adverse events. We selected manuscript including information on subjects developing headache after injection, and such information had to be derived from a structured form (i.e. no free reporting). Pooled estimates and 95% confidence intervals were calculated. Analyses were carried out by vaccine vs. placebo, by first vs. second dose, and by mRNA-based vs. “traditional” vaccines; finally, we addressed the impact of age and gender on post-vaccine headache onset. Results Out of 9338 records, 84 papers were included in the review, accounting for 1.57 million participants, 94% of whom received BNT162b2 or ChAdOx1. Headache was generally the third most common AE: it was detected in 22% (95% CI 18–27%) of subjects after the first dose of vaccine and in 29% (95% CI 23–35%) after the second, with an extreme heterogeneity. Those receiving placebo reported headache in 10–12% of cases. No differences were detected across different vaccines or by mRNA-based vs. “traditional” ones. None of the studies reported information on headache features. A lower prevalence of headache after the first injection of BNT162b2 among older participants was shown. Conclusions Our results show that vaccines are associated to a two-fold risk of developing headache within 7 days from injection, and the lack of difference between vaccine types enable to hypothesize that headache is secondary to systemic immunological reaction than to a vaccine-type specific reaction. Some descriptions report onset within the first 24 h and that in around one-third of the cases, headache has migraine-like features with pulsating quality, phono and photophobia; in 40–60% of the cases aggravation with activity is observed. The majority of patients used some medication to treat headache, the one perceived as the most effective being acetylsalicylic acid.

Published
2022

172. The Global Campaign turns 18:a brief review of its activities and achievements

Author

Steiner, Timothy J., Birbeck, Gretchen L., Jensen, Rigmor H., Martelletti, Paolo, Stovner, Lars Jacob, Uluduz, Derya, Leonardi, Matilde, Olesen, Jes, Katsarava, Zaza, Steiner, Timothy J., Birbeck, Gretchen L., Jensen, Rigmor H., Martelletti, Paolo, Stovner, Lars Jacob, Uluduz, Derya, Leonardi, Matilde, Olesen, Jes, and Katsarava, Zaza

Abstract

The Global Campaign against Headache, as a collaborative activity with the World Health Organization (WHO), was formally launched in Copenhagen in March 2004. In the month it turns 18, we review its activities and achievements, from initial determination of its strategic objectives, through partnerships and project management, knowledge acquisition and awareness generation, to evidence-based proposals for change justified by cost-effectiveness analysis.

Published
2022

177. Neurological and Mental Health Symptoms Associated with Post-COVID-19 Disability in a Sample of Patients Discharged from a COVID-19 Ward: A Secondary Analysis

Author

Cacciatore, Martina, primary, Raggi, Alberto, additional, Pilotto, Andrea, additional, Cristillo, Viviana, additional, Guastafierro, Erika, additional, Toppo, Claudia, additional, Magnani, Francesca G., additional, Sattin, Davide, additional, Mariniello, Arianna, additional, Silvaggi, Fabiola, additional, Cotti Piccinelli, Stefano, additional, Zoppi, Nicola, additional, Bonzi, Giulio, additional, Gipponi, Stefano, additional, Libri, Ilenia, additional, Bezzi, Michela, additional, Martelletti, Paolo, additional, Leonardi, Matilde, additional, and Padovani, Alessandro, additional

Published
2022
Full Text
View/download PDF

181. Additional file 1 of European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention – 2022 update

Author

Sacco, Simona, Amin, Faisal Mohammad, Ashina, Messoud, Bendtsen, Lars, Deligianni, Christina I., Gil-Gouveia, Raquel, Katsarava, Zaza, MaassenVanDenBrink, Antoinette, Martelletti, Paolo, Mitsikostas, Dimos-Dimitrios, Ornello, Raffaele, Reuter, Uwe, Sanchez-del-Rio, Margarita, Sinclair, Alexandra J., Terwindt, Gisela, Uluduz, Derya, Versijpt, Jan, and Lampl, Christian

Subjects
Data_FILES, ComputingMilieux_COMPUTERSANDSOCIETY, InformationSystems_MISCELLANEOUS
Abstract

Additional file 1. Conflicts of interest disclosures.

Published
2022
Full Text
View/download PDF

182. Additional file 1 of European Headache Federation (EHF) consensus on the definition of effective treatment of a migraine attack and of triptan failure

Author

Sacco, Simona, Lampl, Christian, Amin, Faisal Mohammad, Braschinsky, Mark, Deligianni, Christina, Uludüz, Derya, Versijpt, Jan, Ducros, Anne, Gil-Gouveia, Raquel, Katsarava, Zaza, Martelletti, Paolo, Ornello, Raffaele, Raffaelli, Bianca, Boucherie, Deirdre M., Pozo-Rosich, Patricia, Sanchez-del-Rio, Margarita, Sinclair, Alexandra, Maassen van den Brink, Antoinette, and Reuter, Uwe

Abstract

Additional file 1: Figure S1. PRISMA flowchart of systematic review. Table S1. Pain relief at different timepoints. Table S2. Pain relief and pain-free at 2 hours. Table S3. Headache recurrence within 24 hours. Table S4. Rescue medication. Table S5. Response in triptan non-responders. Table S6. Comparisons of different triptan formulations. Table S7. Comparisons between early and late treatment with triptans. Table S8. Agreement on questions submitted in Round 1. Table S9. Conflicts of interest of the authors.

Published
2022
Full Text
View/download PDF

183. Additional file 1 of Headache onset after vaccination against SARS-CoV-2: a systematic literature review and meta-analysis

Author

Castaldo, Matteo, Waliszewska-Prosół, Marta, Koutsokera, Maria, Robotti, Micaela, Straburzyński, Marcin, Apostolakopoulou, Loukia, Capizzi, Mariarita, Çibuku, Oneda, Ambat, Fidel Dominique Festin, Frattale, Ilaria, Gadzhieva, Zukhra, Gallo, Erica, Gryglas-Dworak, Anna, Halili, Gleni, Jusupova, Asel, Koperskaya, Yana, Leheste, Alo-Rainer, Manzo, Maria Laura, Marcinnò, Andrea, Marino, Antonio, Mikulenka, Petr, Ong, Bee Eng, Polat, Burcu, Popovic, Zvonimir, Rivera-Mancilla, Eduardo, Roceanu, Adina Maria, Rollo, Eleonora, Romozzi, Marina, Ruscitto, Claudia, Scotto di Clemente, Fabrizio, Strauss, Sebastian, Taranta, Valentina, Terhart, Maria, Tychenko, Iryna, Vigneri, Simone, Misiak, Blazej, Martelletti, Paolo, and Raggi, Alberto

Subjects
Data_FILES
Abstract

Additional file 1.

Published
2022
Full Text
View/download PDF

184. Hormonal contraceptives and risk of ischemic stroke in women with migraine: a consensus statement from the European Headache Federation (EHF) and the European Society of Contraception and Reproductive Health (ESC)

Author

Sacco, Simona, Merki-Feld, Gabriele S., Ægidius, Karen Lehrmann, Bitzer, Johannes, Canonico, Marianne, Kurth, Tobias, Lampl, Christian, Lidegaard, Øjvind, Anne MacGregor, E., MaassenVanDenBrink, Antoinette, Mitsikostas, Dimos-Dimitrios, Nappi, Rossella Elena, Ntaios, George, Sandset, Per Morten, Martelletti, Paolo, and on behalf of the European Headache Federation (EHF) and the European Society of Contraception and Reproductive Health (ESC)

Published
2017
Full Text
View/download PDF

186. Comment on "What predicts citation counts and translational impact in headache research? A machine learning analysis".

Author

Petrušić, Igor and Martelletti, Paolo

Subjects
*MACHINE learning, *NATURAL language processing, *CALCITONIN gene-related peptide, *GENERATIVE adversarial networks, *ARTIFICIAL intelligence
Abstract

The letter is a response to an article about the use of machine learning models to predict citation counts and translational impact in headache research. The authors of the letter express their opinions on the methodology, results, discussion, and conclusion of the study. They criticize the omission of a significant amount of data due to missing information and suggest using imputation methods to overcome this issue. They also question the inclusion of certain types of publications in the analysis and argue that using only original articles would provide more useful predictors. Additionally, they raise concerns about the use of journal information and the potential bias it may introduce. The authors agree that natural language processing models could be useful but caution that current models should be further customized for headache research. They also argue that the selection of years up to 2017 is misleading and suggest using the same model for papers published from 2018 onwards. Overall, they commend the study and suggest further research in the field. [Extracted from the article]

Published
2024
Full Text
View/download PDF

192. Comparison of Computerized Prescription Support Systems in COVID-19 Patients: INTERCheck and Drug-PIN

Author

Martocchia, Antonio, primary, Bruscia, Clara, additional, Conforti, Giulia, additional, Falangone, Francesca, additional, Marini, Valentina, additional, Pennica, Alfredo, additional, Pezzuto, Aldo, additional, March, Massimiliano Rocchietti, additional, Sentimentale, Alberto, additional, Spuntarelli, Valerio, additional, Tafaro, Laura, additional, Ricci, Alberto, additional, Simmaco, Maurizio, additional, Sesti, Giorgio, additional, Preissner, Robert, additional, and Martelletti, Paolo, additional

Published
2021
Full Text
View/download PDF

193. How Does COVID-19 Pandemic Impact on Incidence of Clostridioides difficile Infection and Exacerbation of Its Gastrointestinal Symptoms?

Author

Azimirad, Masoumeh, primary, Noori, Maryam, additional, Raeisi, Hamideh, additional, Yadegar, Abbas, additional, Shahrokh, Shabnam, additional, Asadzadeh Aghdaei, Hamid, additional, Bentivegna, Enrico, additional, Martelletti, Paolo, additional, Petrosillo, Nicola, additional, and Zali, Mohammad Reza, additional

Published
2021
Full Text
View/download PDF

194. A bedside ultrasound protocol to the measurement of the systemic vascular resistances: Preliminary results in the patients with sepsis.

Author

Martocchia, Antonio, Piccoli, Cinzia, Notarangelo, Michele Fortunato, Bentivegna, Enrico, Sergi, Daniela, Luciani, Michelangelo, Barlattani, Michela, Sesti, Giorgio, and Martelletti, Paolo

Subjects
VASCULAR resistance, NEONATAL sepsis, CENTRAL venous pressure, SEPSIS, CARDIAC output, GLOMERULAR filtration rate
Abstract

BACKGROUND: The use of the ultrasound (US) bedside examination is increasing for the detailed evaluation of the hemodynamic parameters, allowing the physicians to set the appropriate therapeutic strategies with greater precision. OBJECTIVE: The aim of this study is to evaluate the hemodynamic parameters (the cardiac output or CO, the central venous pressure or CVP and the systemic vascular resistance or SVR) in the patients with sepsis, by using a bedside US approach. METHODS: We consecutively enrolled n.82 patients of S.Andrea Hospital (n.47 with sepsis and n.35 without sepsis), examining the hemodynamic parameters by a bedside US evaluation. RESULTS: The incidence of sepsis was more than 50% of cases. The patients with sepsis presented higher comorbidity and polypharmacy (p < 0.01, p < 0.001), with increased creatinine (p < 0.001) and consequent esteemed glomerular filtration rate (p < 0.01), C-reactive protein (p < 0.01), SOFA (Sepsis-related Organ Failure Assessment) score (p < 1.58×10–7) and reduced SVR (p < 0.05). The SOFA score was inversely related to the SVR (p < 0.05). CONCLUSIONS: To our best knowledge, this is the first study with a bedside US protocol to measure SVR, beyond the abdominal and cardiac qualitative evaluation. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

195. OnabotulinumtoxinA Treatment in Chronic Migraine: Investigation of Its Effects on Disability, Headache and Neck Pain Intensity.

Author

Onan, Dilara, Bentivegna, Enrico, and Martelletti, Paolo

Subjects
SUMATRIPTAN, NECK pain, BOTULINUM A toxins, PAIN measurement, HEADACHE, MIGRAINE
Abstract

Neck disability and pain are frequently encountered problems in patients with chronic migraine (CM). The long-term stimuli of neurons in the trigeminocervical junction may explain this situation. OnabotulinumtoxinA (ONA) treatment is one of the proven treatments for CM; however, there is no study data on the efficacy of ONA treatment on neck disability and pain in CM patients. Therefore, we aimed to investigate the effect of ONA treatment on disability, neck pain and headache intensity in CM patients. One hundred thirty-four patients who met the inclusion criteria were included in the study. ONA treatment was administered at a dose of 195 U to 39 sites in total as per Follow-the-Pain PREEMPT protocol. The disability was evaluated with the Neck Disability Index and the Migraine Disability Assessment; pain intensity was evaluated with the Visual Analogue Scale; the monthly number of headache days were recorded; quality of life was evaluated with the Headache Impact Test. All assessments were recorded at baseline and 3 months after treatment. After the treatment, neck–migraine disabilities decreased from severe to mild for neck and moderate for migraine (p < 0.001). Neck pain and headache intensities decreased by almost half (p < 0.001). The median number of monthly headache days decreased from 20 days to 6 days (p < 0.000). The quality-of-life level decreased significantly from severe to substantial level (p < 0.001). According to our results, ONA treatment was effective in reducing neck-related problems in CM patients. Long-term follow-up results may provide researchers with more comprehensive results in terms of the treatment of chronic migraine–neck-related problems. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results